Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
1. 系统已在2026-03-16 16:12:28对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/s2468-1253(25)00198-0
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S2468125325001980
其他信息:
出版社: Elsevier BV
作者: Kaichun Wu; Changqing Zheng; Qian Cao; Yijuan Ding; Xiang Gao; Jie Zhong; Cheng-Tang Chiu; Hu Zhang; Xin Wang; Bangmao Wang; Jie Liang; Xiaowei Liu; Yongjian Zhou; Baohong Xu; Tae-Oh Kim; Xizhong Shen; Dongfeng Chen; Weichang Chen; Yulan Liu; Jun Shen; Fei Liu; Xiaoyun Ding; Qiang Zhan; Jen-Wei Chou; Sandra Zeng; Yun Lin; Lisa Ying; Xia Chen; Zhe Zhang; Ning Wang; Xiaocang Cao; Lingna Ye; Qinwen Huang; Hairong Zhang; Hongjie Zhang; Zhenyu Zhang; Xiaohua Hou; Huahong Wang; Jinhai Wang; Feng Pan; Mei Liu; Fangyu Wang; Deliang Liu; Wensheng Pan; Qizhi Wang; Jin Ding; KyeongOk Kim; Eun Soo Kim; Feng Xu; Kaiguang Zhang; Yisen Huang; Jiangbin Wang; Yadong Lai; Ling Zhang; Hsu-Heng Yen; Wei Wu; Chenggong Yu; Chiyi He; Bai-Sui Feng; Tien-Yu Huang
